CFO of Poniard Pharmaceuticals Inc. (PARD, Financial) Gregory L Weaver buys 2,000 shares of PARD on 04/06/2009 at an average price of $2.07 a share.
Poniard Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the discovery development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin the Company's lead product candidate is a new generation platinum therapy that provides a differentiated spectrum of activity and an improved safety profile. An intravenous chemotherapeutic agent picoplatin is designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin currently is being studied in clinical trials for the treatment of small cell lung colorectal and hormone-refractory prostate cancers. As part of the Company's strategic goal of building a diverse oncology pipeline the Company also is collaborating with the Scripps Florida Research Institute on the discovery of novel small-molecule multi-targeted protein kinase inhibitors. Poniard Pharmaceuticals Inc. has a market cap of $71.46 million; its shares were traded at around $2.06 .
Recent Trades of Poniard Pharmaceuticals Inc. by CEO:
Recent Trades of Poniard Pharmaceuticals Inc. by CFO:
Recent Trades of Poniard Pharmaceuticals Inc. by Directors and Officers:
Poniard Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the discovery development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin the Company's lead product candidate is a new generation platinum therapy that provides a differentiated spectrum of activity and an improved safety profile. An intravenous chemotherapeutic agent picoplatin is designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin currently is being studied in clinical trials for the treatment of small cell lung colorectal and hormone-refractory prostate cancers. As part of the Company's strategic goal of building a diverse oncology pipeline the Company also is collaborating with the Scripps Florida Research Institute on the discovery of novel small-molecule multi-targeted protein kinase inhibitors. Poniard Pharmaceuticals Inc. has a market cap of $71.46 million; its shares were traded at around $2.06 .
Recent Trades of Poniard Pharmaceuticals Inc. by CEO:
- Buy: CEO, Director Gerald Phd Mcmahon bought 7,375 shares of PARD stock on 12/29/2008 at the average price of $1.4; the price of the stock has increased by 47.14% since.
Recent Trades of Poniard Pharmaceuticals Inc. by CFO:
- Buy: CFO Gregory L Weaver bought 2,000 shares of PARD stock on 04/06/2009 at the average price of $2.07; the price of the stock has decreased by 0.48% since.
Recent Trades of Poniard Pharmaceuticals Inc. by Directors and Officers:
- Buy: Director Fred B Craves bought 5,000 shares of PARD stock on 03/27/2009 at the average price of $2.14; the price of the stock has decreased by 3.74% since.
- Buy: Director Fred B Craves bought 15,000 more shares of PARD stock on 03/26/2009 at the average price of $2.1; the price of the stock has decreased by 1.9% since.
- Buy: Director David R Stevens bought 6,450 shares of PARD stock on 01/09/2009 at the average price of $3.44; the price of the stock has decreased by 40.12% since.
- Buy: Director Fred B Craves bought 2,900 shares of PARD stock on 12/22/2008 at the average price of $1.76; the price of the stock has increased by 17.05% since.
- Buy: Director Fred B Craves bought 25,000 more shares of PARD stock on 12/19/2008 at the average price of $1.75; the price of the stock has increased by 17.71% since.
